## Kineret (Anakinra) Prior Authorization Request Form 5586



To be completed and signed by the prescriber. To be used only for prescriptions which are to be filled through the Department of Defense (DoD) TRICARE pharmacy program (TPHARM). Express Scripts is the TPHARM contractor for DoD.

**SPECIAL NOTES:** Kineret and Enbrel are non-formulary (Tier 3) under the DoD Uniform Formulary and carry a higher copay for non-Active duty beneficiaries than Humira, Raptiva, and Amevive, which are formulary (Tier 2). TRICARE does not cover Kineret for Active duty beneficiaries, who pay no co-pay, unless it is determined to be medically necessary *instead of a formulary agent*.

Medical necessity forms are available on the TRICARE Pharmacy website at <a href="http://pec.ha.osd.mil/forms\_criteria.php.">http://pec.ha.osd.mil/forms\_criteria.php.</a>. This form may NOT be used to meet medical necessity requirements. Active duty beneficiaries newly starting on Enbrel or Kineret require both forms.

MAIL ORDER and RETAIL

 The provider may call: 1-866-684-4488 or the completed form may be faxed to: 1-866-684-4477

 The patient may attach the completed form to the prescription and mail it to: Express Scripts, P.O. Box 52150, Phoenix, AZ 85072-9954 or email the form only to:

TpharmPA@express-scripts.com

Prior authorization criteria and a copy of this form are available at: <a href="http://pec.ha.osd.mil/forms">http://pec.ha.osd.mil/forms</a> criteria.php. This prior authorization has no expiration date.

Drug for	which Prior Authorization is requested: Kin	eret (anakinra)	
Step	Please complete patient and physician information (Please Print)		
1	Patient Name: Physician Name:		
	Address:	Address:	
	<u> </u>		
	Sponsor ID#	Phone #:	
	Date of Birth Sec	ure Fax #:	
Step	Please complete the clinical assessment:		
2	1. Is this a continuation of therapy with Kineret?	☐ Yes Please sign and date. See for quantity limits below.	☐ No Please proceed to Question 2
	2. Is the patient at least 18 years of age?	☐ Yes Please proceed to Question 3	☐ No Coverage not approved
	3. Is anakinra being prescribed for the treatment of moderately to severely active rheumatoid arthritis?	☐ Yes Please proceed to Question 4	☐ No Coverage not approved
	4. Will the patient be receiving Humira (adalimumab), Enbrel (etanercept) or Remicade (infliximab) in combination with Kineret?	☐ Yes Coverage not approved	☐ No Please proceed to Question 5
	5. Has the patient had an inadequate response to at least one disease-modifying anti-rheumatic drug (DMARD)?	☐ Yes Please sign and date. See for quantity limits below.	☐ No Coverage not approved
	Quantity Limits: limited to a 4 week supply in retail, and an 8 week supply in mail order.		
Step 3	I certify the above is true to the best of my knowledge. Please sign and date.		
	Prescriber Signature	Date	m. 2000